再生元制药公司(Regeneron Pharmaceuticals, REGN)的评级遭遇下调。投资机构Leerink Partners将其对该公司的投资评级从“跑赢大盘”(Outperform)调降至“与大盘持平”(Market Perform)。与此同时,该机构大幅下调了再生元制药的目标股价,从原先的792美元削减至641美元。
再生元制药公司(Regeneron Pharmaceuticals, REGN)的评级遭遇下调。投资机构Leerink Partners将其对该公司的投资评级从“跑赢大盘”(Outperform)调降至“与大盘持平”(Market Perform)。与此同时,该机构大幅下调了再生元制药的目标股价,从原先的792美元削减至641美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.